Wellington Hospital
Welcome,         Profile    Billing    Logout  
 17 Trials 
25 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hardie, Claire
EXPERT, NCT02889874: EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer

Recruiting
N/A
1167
Europe, RoW
Omission of radiation therapy
Breast Cancer Trials, Australia and New Zealand, Breast International Group, ETOP IBCSG Partners Foundation
Early Stage Breast Carcinoma
10/25
04/26
Taylor, Paul
HIT-Meso, NCT05655078: Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma

Recruiting
N/A
148
Europe
Proton beam therapy
University College, London, Asthma + Lung UK, Mesothelioma UK, University of Sheffield
Malignant Pleural Mesothelioma
03/29
09/29
Young, Paul
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
BoneZone, NCT04608630 / ACTRN12621000085875p: Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

Recruiting
2
450
RoW
Denosumab 60 MG/ML, Prolia, Xgeva, Zoledronic Acid 5Mg/Bag 100Ml Inj, Zometa, Reclast, Aclasta, Sodium Chloride 0.9% or 5% Dextrose Intravenous, Saline, Placebo, Sodium Chloride 0.9% Injection
Australian and New Zealand Intensive Care Research Centre, Department of Health
Critical Illness, Osteoporosis
02/27
02/27
NCT06350734: Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study

Recruiting
N/A
704
US
Non-Interventional Study
Mayo Clinic
Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
01/29
01/29
TTM-2, NCT02908308: Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest

Completed
N/A
1900
Europe, US, RoW
Targeted temperature management to 33°C, Standard care with early treatment of fever
Helsingborgs Hospital, Lund University, Region Skåne - Skånevård SUND, Copenhagen Trial Unit, Center for Clinical Intervention Research, Clinical Trials Sweden, Forum South, Integrated Biobank of Luxembourg
Out-of-hospital Cardiac Arrest
06/22
12/22
NCT06207942: Stepcare Extended Follow-up Substudy

Recruiting
N/A
600
Europe, RoW
Feed back controlled temperature device, High MAP, Deep sedation, Fever control without a device, Low MAP, Minimal sedation
Region Skane, Lund University, The George Institute for Global Health, Australia, Copenhagen Trial Unit, Center for Clinical Intervention Research, Helsinki University Central Hospital
Cardiac Arrest With Successful Resuscitation, Hypoxia, Brain, Cognitive Impairment, Caregiver Burden
06/26
12/26
BALANCE, NCT03005145: Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness

Completed
N/A
3622
Europe, Canada, US, RoW
7 days of adequate antibiotic treatment, 14 days of adequate antibiotic treatment.
Sunnybrook Health Sciences Centre
Bacteremia, Intensive Care, Critically Ill, Sepsis, Mortality, Antimicrobial
05/23
08/23
STEPCARE, NCT05564754 / ACTRN12623001057673: Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation

Recruiting
N/A
3500
Europe, RoW
Feedback-controlled temperature device, High MAP, Deep sedation, Fever control without a device, Low MAP, Minimal sedation
Region Skane, Lund University, Lund, Sweden, Copenhagen Trial Unit, Center for Clinical Intervention Research, The George Institute for Global Health, Australia, HUS Helsinki University Hospitals, Helsinki, Finland, Medical Research Institute of New Zealand Rangahautia Te Ora, Wellington, New Zealand
Cardiac Arrest With Successful Resuscitation, Hypoxia, Brain
12/25
06/26
Harding, Scott V
RESTORE-MI, NCT03998319: A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.

Recruiting
3
445
RoW
Tenecteplase (1/3 systemic weight based dose), TNKase, Sterile water for injection (WFI)
University of Sydney, Genentech, Inc.
STEMI, Elevated IMR (>32)
12/24
12/26
NCT06117150: Pilot Study of the Coronary Spur Stent for In-stent Restenosis (DEEPER CORONARY)

Recruiting
1
10
RoW
Drug-eluting Coronary Spur Stent System
ReFlow Medical, Inc.
In-stent Restenosis
10/24
11/25
Sleep-FAST, NCT05652829: Sleep Duration and Quality in Children

Recruiting
N/A
30
Canada
Memorial University of Newfoundland
Sleep, Food Habits, Lifestyle Factors
02/23
02/23
SWEAT, NCT05652842: Assessing the Impact of Rotational and Shift Work on Sleep, Activity, Energy Balance, and Food Choice in Adults

Recruiting
N/A
45
Canada
Work-type
Memorial University of Newfoundland
Life Style, Shift-Work, Food Preferences
03/23
03/23
Nicholson, Anna
EXPERT, NCT02889874: EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer

Recruiting
N/A
1167
Europe, RoW
Omission of radiation therapy
Breast Cancer Trials, Australia and New Zealand, Breast International Group, ETOP IBCSG Partners Foundation
Early Stage Breast Carcinoma
10/25
04/26
Marshall, Andrew
RECONNECT, NCT04977986 / 2021-002542-33: Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults with Fragile X Syndrome

Recruiting
3
250
Europe, US, RoW
ZYN002 - transdermal gel, cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery), Placebo, Placebo Comparator, Matching Placebo
Zynerba Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc.
Fragile X Syndrome
05/25
05/25
BESCES, NCT06416878: Brief ES for Recovery of Autonomic Function in CES

Recruiting
N/A
40
Europe
Brief ES at the time of decompression for cauda equina syndrome, Brief ES to facilitate mcturition/removal of catheter
University of Liverpool
Cauda Equina Syndrome
09/26
09/26
Ranta, Anna
NCT03385928: STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units

Completed
2
201
Europe, RoW
Tranexamic Acid, Normal saline, 0.9%NaCl
Neuroscience Trials Australia, The Florey Institute of Neuroscience and Mental Health
Intracerebral Haemorrhage
05/23
05/23
Boljonis, Brianne
NCT03872947: A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Recruiting
1
187
Europe, US
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Toray Industries, Inc
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
03/25
03/25
Tan, Nicole Isabella
CALIPSO, NCT05447559: Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study

Recruiting
4
9180
RoW
Cefazolin, Water for injection
Monash University, The Australian and New Zealand College of Anaesthetists (ANZCA)
Surgical Site Infection
01/27
06/27
Warzee, Jean-Marie
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Recruiting
N/A
35000
Europe, Canada, US, RoW
CHDI Foundation, Inc.
Huntington's Disease
01/62
01/62
Supiot, Frédéric
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Recruiting
N/A
35000
Europe, Canada, US, RoW
CHDI Foundation, Inc.
Huntington's Disease
01/62
01/62
Chembo, Caroline
TEACH-PD CRCT, NCT03816111: Targeted Education ApproaCH to Improve Peritoneal Dialysis Outcomes Trial

Active, not recruiting
N/A
1500
RoW
TEACH-PD Training Curriculum, Current standard PD training
The University of Queensland, The HOME Network, Australia and New Zealand Dialysis and Transplant Registry, New Zealand Peritoneal Dialysis Registry
Kidney Disease, Chronic, Peritoneal Dialysis Catheter-Associated Peritonitis, Peritoneal Dialysis Catheter Exit Site Infection, Peritoneal Dialysis Catheter Tunnel Infection
03/25
04/25
Barton, Sarah
FINER, NCT04650581: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Active, not recruiting
3
250
Canada, RoW
Ipatasertib, Fulvestrant, Placebo
Canadian Cancer Trials Group, Hoffmann-La Roche
Breast Cancer
12/24
12/26
Bourke, David
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Recruiting
N/A
35000
Europe, Canada, US, RoW
CHDI Foundation, Inc.
Huntington's Disease
01/62
01/62
Goode, Liz
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Recruiting
N/A
35000
Europe, Canada, US, RoW
CHDI Foundation, Inc.
Huntington's Disease
01/62
01/62

Download Options